Amylin, Takeda call off obesity treatment

San Diego: Amylin Pharmaceuticals Inc. and Takeda Pharmaceutical Co. Ltd. said Thursday that they are discontinuing development of pramlintide/metreleptin, a combination therapy to treat obesity.

The companies said the decision was based on a commercial assessment. Amylin`s senior vice president of research, Christian Weyer, said that in the future, the hope is to develop a similar treatment with "less frequent dosing."

Neither company expects to revise their latest fiscal 2011 guidance because of the development stoppage.

Bureau Report

By continuing to use the site, you agree to the use of cookies. You can find out more by clicking this link